(Mycobacteria tuberculosis)

Similar documents
Appendix B: Provincial Case Definitions for Reportable Diseases

Tuberculosis Exposure Control Plan for Low Risk Dental Offices

Clinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4

Pregnancy and Tuberculosis. Information for clinicians

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Childhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine

Risk for Tuberculosis in Swiss Hospitals. Content. Introduction. Dr. med. Alexander Turk Zürcher Höhenklinik Wald

Tuberculosis: FAQs. What is the difference between latent TB infection and TB disease?

X-Plain Pediatric Tuberculosis Reference Summary

Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

CDC TB Testing Guidelines and Recent Literature Update

IMA Knowledge June, 2015

Medical College, Raipur (C.G.), India 4 MD Community Medicine, Department of Community Medicine, Pt. J.N.M. Medical College, Raipur

09/27/2006 Centers for Disease Control and Prevention Division of Tuberculosis Elimination

Performance Evaluation and Clinical Application of MTB NAAT in Orange County, CA. Minoo Ghajar Orange County Public Health Laboratory

Table. Positive Purified Protein Derivative Results (Pediatrics In Review Apr 2008)

Patient Education CONTENTS. Introduction


Regulations for Tuberculosis Control in Minnesota Health Care Settings

Interim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas

Assisted Living - TB Risk Assessment

AMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS

Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

How To Treat Tuberculosis

Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis. Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva

Paediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation

MANAGEMENT OF TUBERCULOSIS IN PRISONS: Guidance for prison healthcare teams

TB preventive therapy in children. Introduction

What is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, Frequently Asked Questions

Recent Advances in The Treatment of Mycobacterium Tuberculosis

Chapter 3 Testing for Tuberculosis Infection and Disease

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

TUBERCULOSIS CONTROL INDIA

San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection

Tuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions

SASKATCHEWAN PROVINCIAL TUBERCULOSIS STRATEGY

Management of Tuberculosis: Indian Guidelines

PEOSH Model Tuberculosis Infection Control Program

Mycobacteriosis and HIV infection: the new public health challenge

Long-term Care - TB Risk Assessment

Haley Blake, BA Senior Disease Investigation and Intervention Specialist Southern Nevada Health District

Transmission & Pathogenesis of Tuberculosis

Tuberculosis OUR MISSION THE OPPORTUNITY

Drug-resistant Tuberculosis

FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT

Chapter 8 Community Tuberculosis Control

DIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS)

Pediatric Latent TB Diagnosis and Treatment

TB CARE EARLY DETECTION AND PREVENTION OF TUBERCULOSIS (TB) IN CHILDREN. Risk factors in children acquiring TB:

Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET

TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016

Antimicrobial Stewardship for Hospital Acquired Infection Prevention: Focus on C. difficile infection

Solid Organ Transplantation

Borderless Diseases By Sunny Thai

Age In London TB is more common in younger adults aged years and peaks in the age group (3).

Questions and Answers About Tuberculosis

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California

Clinical Scenarios In Childhood TB. Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention

TUBERCULOSIS PLEURAL EFFUSION - MANAGEMENT

Are Booster Doses of Hepatitis B Vaccine Necessary?

Tuberculosis Prevention and Control Protocol, 2008

Tuberculosis Policy and Procedure Manual 2014

General Information on Tuberculosis

An Evaluation of QuantiFERON-TB Gold In-Tube and Immunological Tests for TB Diagnosis in Iraqi Patients

19th Swiss TB Symposium Münchenwiler,

Prevention of Acute COPD exacerbations

Multiple Choice Questions

Journal of Infectious Diseases Advance Access published January 26, 2015

Transcription:

267 2015:25:267-273 (Tuberculosis) (Mycobacteria tuberculosis) 104 9 1 104 10 12 95 (02) 2833-2211 DOI: 10.6526/ICJ.2015.604 104 12

268 (Robert Koch) 1882 1905 1944 (Streptomycin) (Selman Abraham Waksman) 1952 [1] 1985 1989 1995 2001 [2] 2006 16,472 2012 12,338 140 2012 2.7 2012 19 65 [3] (World Health Organization, WHO) 2035 10 (strict aerobes)

269 (Gram stain) (acid fast stain) (Norcardia) (Rhodococcus) 20 2~3 [4] [5] (primary infection) (latent tuberculosis) (reactivation) (reactivation) [6] [7] (Bacelle Calmette- Guèrin, BCG) [8] [9] 7% 3% [10] 104 12

270 [11] 5,000~10,000 [12] 10 [13] (Mycobacterium tuberculosis complex) (Nontubercuulosis mycobacteria, NTM) [14] (Nucleic acid amplification test) [13] X X [15,16] X 10%

271 (Tuberculin skin test) (Interferon- release assays, IGRAs) [16,17] (Directly observed treatment, short course, DOTS) 85% [16,18] 104 12

272 14 8 N95 14 [19] 1. 2003;13: 180-2. 2. 2003;13: 173-9. 3. 2014 2014:111, 183. 4. ( ) 2013:1-6. 5. Nagin D, Pavelchak N, London M, et al: Control of tuberculosis in the workplace engineering controls. Occupational medicine: State of the art reviews 1994;9:609-30. 6. Peter MS, Paula IF: Management of tuberculosis in the United States. N Engl J Med 2001;345:189-200. 7. Annelies van R, Robin W, Madeleine R, et al: Exogenous Reinfection as a Cause of Recurrent Tuberculosis after Curative Treatment. N Engl J Med 1999;341:1174-9. 8. Colditz GA, Brewer TF, Berkey CS, et al: Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702. 9. Naomi E A, Mathuram S, George W C, et al: Long-term Efficacy of BCG Vaccine in American Indians and Alaska NativesA 60-Year Follow-up Study. JAMA 2004;291:2086-91. 10. Stefan Grzybowski: Cost in tuberculosis control. Tubercle 1987;68:33-7. 11. Mase SR, Ramsay A, Ng V, et al: Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007;11:485-95. 12. Thomas W R, Nelson P M: Increased sensitivity of acid fast stain. J Clin Microbiol 1980;11:618-20. 13. LFF Kox: Tests for detection and identification of mycobacteria. How should they be used? Respir Med 1995;89:399-408. 14. Kevin LW, Erin M, Brian K, et al: Pulmonary nontuberculosis Mycobacterial disease: Prevalence and clinical features An emerging public health disease. Am J Respir Criti Care Med 2010;182:977-82. 15. Andreu J, Caceres J, Pallisa E, et al: Radiological manifestations of pulmonary tuberculosis. Eur J Radiol 2004;51:139-49. 16. Haileyesus G, Alberto M, Richard E C, et al: Latent Mycobacterium tuberculosis Infection. N Engl J Med 2015;372:2127-35. 17. 2013;23:46-50. 18. Wo r l d H e a l t h O rg a n i z a t i o n : Tr e a t m e n t of Tuberculosis: Guidelines for National Programmers 3rd edition 2003. 19. () 2009:175-242.

273 A Survey on Tuberculosis: Recall the Past, Gauge the Present, and Look into the Future Chun-Yu Lai Section of Pulmonary Diseases, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan Historically, tuberculosis is an important disease that continues to affect large populations in spite of having identified the causative pathogen, discovering antituberculosis drugs, and developing new diagnostic tools. Increasing acquired immune deficiency syndrome (AIDS) -associated tuberculosis and resistance to multiple anti-tuberculosis drugs have aggravated the scenario. As is known, Mycobacterium tuberculosis causes air-borne infections. BCG decreases the rate of progression to lethal tuberculosis but prevents all infections. The most effective strategy to decrease the prevalence of tuberculosis and cure the infected patients is to quarantine the latter. Accurate diagnosis of active tuberculosis depends on correct sputum collection, acid-fast stain, and culture accompanied by imaging. Unfortunately, increasing prevalence of non-tuberculosis mycobacteria confounds clinical judgment. Moreover, curing patients with tuberculosis is challenging owing to the number of medications that need to be taken for a long duration, and the frequent adverse effects caused by these medications. Directly Observed Treatment Short (DOTS) is effective in improving drug compliance of the patient and decreasing the development of drug resistance. However, it is important to bear in mind that preventive measures are also necessary. Seeking, elucidating, and curing the latent form of tuberculosis will be the next step to eradicating the disease. Key words: Tuberculosis 104 12